A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs

A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs

Many oral anticancer drugs are metabolized by CYP3A. Clinical drug-drug interaction (DDI) studies often only examine the effect of strong CYP3A inhibitors and inducers. The effect of moderate or weak inhibitors or inducers can be examined using physiologically based pharmacokinetic simulations, but...

Full description

Bibliographic Details
Main Authors: Laura Molenaar-Kuijsten, Dorieke E. M. Van Balen, Jos H. Beijnen, Neeltje Steeghs, Alwin D. R. Huitema
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Pharmacology
Subjects:
drug interaction
cytochrome P450 enzyme
CYP3A inhibitor
CYP3A inducer
cancer
kinase inhibitor
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.670862/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.670862/full

Similar Items